Title | Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy (OPUS) |
---|---|
Disease/Condition | Neurology,Epilepsy |
Eligibility Criteria | Click here for eligibility requirements |
Principal Investigator | Alexis Boro, MD |
Contact Name | Darlene Rozon |
Contact Email | drozon@montefiore.org |
IRB/Protocol Number | 17-02-374-01 |
Adult Clinical Trial | Yes |
Pediatric Clinical Trial | No |